Shattuck Labs Says As Of September 30, 2024, Cash And Cash Equivalents And Investments Were Approximately $90.1M That Is Expected To Fund Its Planned Operations Into 2027, Beyond Results From Its Phase 1 Trial Of SL-325

+6.25% Post

Shattuck Labs, Inc.

STTK

1.19

+6.25%

0.00% Post

DR3 Program Milestones Expected in 2025

Preclinical SL-325 data readout from GLP toxicology study in NHPs expected in the first quarter of 2025.
IND filing for SL-325 expected in the third quarter of 2025.
SL-325 Phase 1 clinical trial initiation expected in the third quarter of 2025.
Nomination of lead DR3 bispecific development candidate(s) anticipated in the second half of 2025.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.